Blood Test Predicts Alzheimer's Onset Age | NIH Study
Explore the NIH-funded blood test using p-tau217 that predicts Alzheimer's symptom onset within 3-4 years, led by WashU researchers. Implications for trials and prevention.
No reviews yet. Be the first to rate Kellen!
Kellen Petersen is an Instructor in the Department of Neurology at Washington University in St. Louis, where he joined the Fluid Biomarker Core Lab in March 2024. He received a PhD in Applied Mathematics from the Courant Institute of Mathematical Sciences at New York University. Following his doctoral work, he served as a postdoctoral research fellow at the Albert Einstein College of Medicine, where he applied statistical models and machine learning approaches to examine relationships between biomarkers of Alzheimer’s disease, cognition, and disease progression. His work has also addressed methods for understanding Alzheimer’s disease heterogeneity and developing diagnostic and prognostic tools.
His current research interests center on the relationship between Alzheimer’s disease blood-based biomarkers and cognition. Recent publications include “Predicting onset of symptomatic Alzheimer’s disease with plasma p-tau217 clocks,” published in Nature Medicine in March 2026, and “A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials,” published in Neurology in 2025. Petersen maintains an active research profile with contributions to studies on cognitive function, tau pathology, and inflammatory cytokines in Alzheimer’s disease.
Professional Email: null
Explore the NIH-funded blood test using p-tau217 that predicts Alzheimer's symptom onset within 3-4 years, led by WashU researchers. Implications for trials and prevention.
A new blood test using p-tau217 accurately predicts when Alzheimer's symptoms will begin, offering 3-4 year precision from Washington University research.
Explore the new blood test clock from WashU Medicine that predicts Alzheimer's symptoms 3-4 years accurately using p-tau217 levels, implications for trials and patients.